| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pancreatic Neoplasms | 11 | 2022 | 332 | 2.420 |
Why?
|
| Colorectal Neoplasms | 8 | 2022 | 561 | 2.040 |
Why?
|
| Rectal Neoplasms | 3 | 2016 | 75 | 1.370 |
Why?
|
| Epithelial-Mesenchymal Transition | 4 | 2014 | 135 | 1.300 |
Why?
|
| Transcription Factors | 3 | 2014 | 753 | 0.970 |
Why?
|
| Lymphatic Metastasis | 6 | 2015 | 274 | 0.890 |
Why?
|
| Sarcoma | 2 | 2013 | 70 | 0.830 |
Why?
|
| Antibodies, Monoclonal | 5 | 2015 | 511 | 0.820 |
Why?
|
| Sentinel Lymph Node Biopsy | 4 | 2014 | 53 | 0.780 |
Why?
|
| Drug Resistance, Neoplasm | 6 | 2014 | 332 | 0.760 |
Why?
|
| Graft vs Host Disease | 1 | 2022 | 163 | 0.710 |
Why?
|
| ErbB Receptors | 2 | 2015 | 239 | 0.680 |
Why?
|
| Chemoradiotherapy | 2 | 2016 | 54 | 0.650 |
Why?
|
| Antimetabolites, Antineoplastic | 4 | 2013 | 77 | 0.640 |
Why?
|
| Fluorouracil | 4 | 2014 | 130 | 0.610 |
Why?
|
| Cell Line, Tumor | 15 | 2022 | 1851 | 0.600 |
Why?
|
| Metabolic Syndrome | 2 | 2016 | 191 | 0.560 |
Why?
|
| Deoxycytidine | 3 | 2014 | 83 | 0.550 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 2 | 2007 | 100 | 0.520 |
Why?
|
| Colostomy | 1 | 2015 | 15 | 0.510 |
Why?
|
| Ileostomy | 1 | 2015 | 14 | 0.510 |
Why?
|
| MicroRNAs | 3 | 2014 | 447 | 0.500 |
Why?
|
| ras Proteins | 1 | 2015 | 102 | 0.480 |
Why?
|
| Neoplastic Stem Cells | 1 | 2014 | 84 | 0.440 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 2013 | 35 | 0.440 |
Why?
|
| Extremities | 1 | 2013 | 49 | 0.440 |
Why?
|
| Mice | 9 | 2022 | 8474 | 0.440 |
Why?
|
| Lymph Node Excision | 2 | 2013 | 91 | 0.440 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2013 | 28 | 0.440 |
Why?
|
| Pneumatosis Cystoides Intestinalis | 1 | 2013 | 5 | 0.440 |
Why?
|
| Receptors, Transferrin | 1 | 2013 | 18 | 0.440 |
Why?
|
| Genes, p53 | 1 | 2013 | 41 | 0.430 |
Why?
|
| Calcitriol | 1 | 2013 | 106 | 0.430 |
Why?
|
| Jejunostomy | 1 | 2013 | 26 | 0.430 |
Why?
|
| Neovascularization, Pathologic | 5 | 2007 | 183 | 0.420 |
Why?
|
| Immunocompetence | 1 | 2011 | 19 | 0.400 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2012 | 446 | 0.380 |
Why?
|
| Disease Models, Animal | 3 | 2022 | 2550 | 0.370 |
Why?
|
| Lymph Nodes | 1 | 2012 | 258 | 0.370 |
Why?
|
| Humans | 42 | 2022 | 68618 | 0.370 |
Why?
|
| Liver Neoplasms | 2 | 2013 | 334 | 0.370 |
Why?
|
| Snail Family Transcription Factors | 3 | 2014 | 31 | 0.330 |
Why?
|
| Pancreas | 3 | 2015 | 225 | 0.330 |
Why?
|
| Breast Neoplasms | 4 | 2013 | 1536 | 0.320 |
Why?
|
| Cadherins | 4 | 2013 | 93 | 0.290 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2013 | 304 | 0.280 |
Why?
|
| Nitroarginine | 1 | 2006 | 2 | 0.270 |
Why?
|
| Nitric Oxide Synthase | 2 | 2006 | 163 | 0.270 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2006 | 32 | 0.270 |
Why?
|
| Cell Movement | 5 | 2013 | 630 | 0.260 |
Why?
|
| Neoplasm Metastasis | 3 | 2007 | 306 | 0.260 |
Why?
|
| Carcinoma, Ductal | 1 | 2005 | 14 | 0.260 |
Why?
|
| Pancreaticoduodenectomy | 2 | 2015 | 34 | 0.260 |
Why?
|
| Neoadjuvant Therapy | 2 | 2016 | 104 | 0.260 |
Why?
|
| NF-kappa B | 2 | 2004 | 432 | 0.260 |
Why?
|
| Mastectomy, Segmental | 1 | 2005 | 64 | 0.260 |
Why?
|
| Carcinoma in Situ | 1 | 2005 | 47 | 0.250 |
Why?
|
| Postoperative Complications | 1 | 2013 | 1615 | 0.250 |
Why?
|
| Carcinoma | 2 | 2005 | 215 | 0.250 |
Why?
|
| Neoplasm Transplantation | 4 | 2013 | 160 | 0.240 |
Why?
|
| Camptothecin | 1 | 2004 | 39 | 0.240 |
Why?
|
| Animals | 12 | 2022 | 20881 | 0.230 |
Why?
|
| Common Bile Duct Neoplasms | 1 | 2004 | 12 | 0.230 |
Why?
|
| Stomach Neoplasms | 1 | 2004 | 64 | 0.230 |
Why?
|
| Cell Division | 4 | 2011 | 541 | 0.230 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2005 | 235 | 0.220 |
Why?
|
| Carcinoma, Merkel Cell | 2 | 2014 | 12 | 0.220 |
Why?
|
| Pancreatitis | 2 | 2004 | 279 | 0.210 |
Why?
|
| Survival Rate | 4 | 2013 | 1056 | 0.210 |
Why?
|
| Neoplasm Invasiveness | 4 | 2013 | 369 | 0.200 |
Why?
|
| Male | 17 | 2016 | 37321 | 0.200 |
Why?
|
| Nucleotides | 1 | 2022 | 29 | 0.200 |
Why?
|
| Genes, ras | 1 | 2022 | 46 | 0.200 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2022 | 124 | 0.200 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2022 | 87 | 0.200 |
Why?
|
| Organoplatinum Compounds | 4 | 2014 | 21 | 0.200 |
Why?
|
| Middle Aged | 13 | 2016 | 21147 | 0.190 |
Why?
|
| Aged, 80 and over | 6 | 2015 | 4848 | 0.190 |
Why?
|
| Female | 19 | 2016 | 38074 | 0.190 |
Why?
|
| Tumor Microenvironment | 1 | 2022 | 213 | 0.190 |
Why?
|
| Carcinoid Tumor | 3 | 2007 | 20 | 0.190 |
Why?
|
| SEER Program | 4 | 2014 | 153 | 0.180 |
Why?
|
| Retrospective Studies | 7 | 2016 | 7277 | 0.180 |
Why?
|
| Mutation | 2 | 2022 | 1213 | 0.180 |
Why?
|
| Cell Proliferation | 5 | 2022 | 1174 | 0.170 |
Why?
|
| Aged | 10 | 2015 | 14862 | 0.170 |
Why?
|
| Apoptosis | 5 | 2013 | 1641 | 0.160 |
Why?
|
| Cell Adhesion | 2 | 2013 | 324 | 0.160 |
Why?
|
| Head and Neck Neoplasms | 2 | 2014 | 561 | 0.150 |
Why?
|
| Mesoderm | 3 | 2007 | 231 | 0.150 |
Why?
|
| Biomarkers, Tumor | 3 | 2016 | 508 | 0.140 |
Why?
|
| Neoplasm Staging | 3 | 2016 | 800 | 0.140 |
Why?
|
| HT29 Cells | 2 | 2014 | 42 | 0.140 |
Why?
|
| Epithelium | 2 | 2007 | 172 | 0.140 |
Why?
|
| Colonic Neoplasms | 2 | 2012 | 299 | 0.140 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2013 | 756 | 0.140 |
Why?
|
| Pancreatectomy | 2 | 2015 | 129 | 0.130 |
Why?
|
| Bile Ducts, Intrahepatic | 1 | 2016 | 14 | 0.130 |
Why?
|
| Antineoplastic Agents | 4 | 2008 | 1070 | 0.130 |
Why?
|
| Cholangiocarcinoma | 1 | 2016 | 20 | 0.130 |
Why?
|
| Lung Neoplasms | 1 | 2005 | 1173 | 0.130 |
Why?
|
| Tumor Burden | 2 | 2013 | 132 | 0.130 |
Why?
|
| Paraganglioma | 1 | 2015 | 8 | 0.130 |
Why?
|
| Immunohistochemistry | 4 | 2006 | 1174 | 0.130 |
Why?
|
| Bile Duct Neoplasms | 1 | 2016 | 39 | 0.130 |
Why?
|
| Mice, Inbred C57BL | 2 | 2013 | 2791 | 0.130 |
Why?
|
| Ampulla of Vater | 1 | 2015 | 34 | 0.130 |
Why?
|
| Cetuximab | 1 | 2015 | 19 | 0.130 |
Why?
|
| Carcinoma, Papillary | 1 | 2015 | 35 | 0.130 |
Why?
|
| Anniversaries and Special Events | 1 | 2015 | 12 | 0.130 |
Why?
|
| Anastomosis, Surgical | 1 | 2015 | 104 | 0.130 |
Why?
|
| Chemoradiotherapy, Adjuvant | 1 | 2015 | 33 | 0.130 |
Why?
|
| Combined Modality Therapy | 3 | 2013 | 951 | 0.120 |
Why?
|
| Vascular Endothelial Growth Factor A | 4 | 2008 | 219 | 0.120 |
Why?
|
| HCT116 Cells | 1 | 2014 | 63 | 0.120 |
Why?
|
| Gastrostomy | 1 | 2015 | 110 | 0.120 |
Why?
|
| Radiography, Dual-Energy Scanned Projection | 1 | 2015 | 92 | 0.120 |
Why?
|
| Adult | 10 | 2015 | 21403 | 0.120 |
Why?
|
| Signal Transduction | 5 | 2022 | 2689 | 0.120 |
Why?
|
| Transfection | 2 | 2014 | 782 | 0.120 |
Why?
|
| RNA, Messenger | 3 | 2013 | 1664 | 0.120 |
Why?
|
| Proportional Hazards Models | 2 | 2013 | 792 | 0.120 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2014 | 30 | 0.120 |
Why?
|
| Induction Chemotherapy | 1 | 2014 | 39 | 0.110 |
Why?
|
| Calcium Channel Agonists | 1 | 2013 | 18 | 0.110 |
Why?
|
| Vimentin | 1 | 2013 | 47 | 0.110 |
Why?
|
| Receptors, Calcitriol | 1 | 2013 | 49 | 0.110 |
Why?
|
| Gamma Rays | 1 | 2013 | 64 | 0.110 |
Why?
|
| Neoplasm Grading | 1 | 2013 | 111 | 0.110 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2013 | 282 | 0.110 |
Why?
|
| Treatment Outcome | 4 | 2016 | 7029 | 0.110 |
Why?
|
| Nanomedicine | 1 | 2013 | 19 | 0.110 |
Why?
|
| Single-Chain Antibodies | 1 | 2013 | 15 | 0.110 |
Why?
|
| Peroxiredoxins | 1 | 2013 | 34 | 0.110 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2013 | 111 | 0.110 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2014 | 468 | 0.110 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2013 | 209 | 0.110 |
Why?
|
| Sarcoma, Clear Cell | 1 | 2012 | 8 | 0.100 |
Why?
|
| Sarcoma, Synovial | 1 | 2012 | 11 | 0.100 |
Why?
|
| False Negative Reactions | 1 | 2012 | 63 | 0.100 |
Why?
|
| Rhabdomyosarcoma | 1 | 2012 | 36 | 0.100 |
Why?
|
| Gene Transfer Techniques | 1 | 2013 | 173 | 0.100 |
Why?
|
| Comorbidity | 1 | 2016 | 1426 | 0.100 |
Why?
|
| Tumor Cells, Cultured | 1 | 2013 | 852 | 0.100 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2015 | 689 | 0.100 |
Why?
|
| Monte Carlo Method | 1 | 2012 | 124 | 0.100 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 2 | 2008 | 13 | 0.100 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2013 | 710 | 0.100 |
Why?
|
| Mice, Nude | 3 | 2007 | 294 | 0.100 |
Why?
|
| Markov Chains | 1 | 2012 | 133 | 0.100 |
Why?
|
| Risk Factors | 3 | 2016 | 5731 | 0.100 |
Why?
|
| Blotting, Western | 1 | 2013 | 954 | 0.100 |
Why?
|
| Prognosis | 2 | 2013 | 2093 | 0.090 |
Why?
|
| Genetic Therapy | 1 | 2013 | 291 | 0.090 |
Why?
|
| Phenotype | 1 | 2014 | 947 | 0.090 |
Why?
|
| Adenocarcinoma | 1 | 2014 | 475 | 0.090 |
Why?
|
| Spleen | 1 | 2011 | 301 | 0.090 |
Why?
|
| Radiotherapy Dosage | 2 | 2014 | 125 | 0.090 |
Why?
|
| Bayes Theorem | 1 | 2012 | 307 | 0.090 |
Why?
|
| Nanoparticles | 1 | 2013 | 254 | 0.090 |
Why?
|
| United States | 4 | 2014 | 7367 | 0.080 |
Why?
|
| Ileal Neoplasms | 1 | 2007 | 5 | 0.080 |
Why?
|
| Intestinal Perforation | 1 | 2007 | 35 | 0.070 |
Why?
|
| Liver Neoplasms, Experimental | 1 | 2007 | 38 | 0.070 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2007 | 42 | 0.070 |
Why?
|
| Active Transport, Cell Nucleus | 1 | 2007 | 55 | 0.070 |
Why?
|
| Neoplasms | 3 | 2007 | 1667 | 0.070 |
Why?
|
| Platelet Endothelial Cell Adhesion Molecule-1 | 1 | 2006 | 29 | 0.070 |
Why?
|
| Severity of Illness Index | 1 | 2011 | 1851 | 0.070 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 1 | 2006 | 24 | 0.070 |
Why?
|
| Frozen Sections | 1 | 2005 | 14 | 0.070 |
Why?
|
| Intraoperative Period | 1 | 2005 | 62 | 0.070 |
Why?
|
| Blood Vessels | 1 | 2006 | 102 | 0.060 |
Why?
|
| Skin Neoplasms | 2 | 2012 | 375 | 0.060 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2015 | 2324 | 0.060 |
Why?
|
| Vascular Endothelial Growth Factors | 1 | 2005 | 30 | 0.060 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2005 | 125 | 0.060 |
Why?
|
| Random Allocation | 1 | 2006 | 442 | 0.060 |
Why?
|
| Intestinal Polyps | 1 | 2004 | 15 | 0.060 |
Why?
|
| Duodenal Neoplasms | 1 | 2004 | 9 | 0.060 |
Why?
|
| Adenomatous Polyposis Coli | 1 | 2004 | 26 | 0.060 |
Why?
|
| Hepatocyte Growth Factor | 1 | 2005 | 63 | 0.060 |
Why?
|
| Leucovorin | 1 | 2004 | 35 | 0.060 |
Why?
|
| Cell Survival | 1 | 2007 | 901 | 0.060 |
Why?
|
| Nitric Oxide | 1 | 2006 | 382 | 0.060 |
Why?
|
| False Positive Reactions | 1 | 2004 | 95 | 0.060 |
Why?
|
| Radionuclide Imaging | 1 | 2004 | 166 | 0.060 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2004 | 88 | 0.060 |
Why?
|
| Protein Structure, Tertiary | 1 | 2005 | 322 | 0.060 |
Why?
|
| Radiopharmaceuticals | 1 | 2004 | 114 | 0.060 |
Why?
|
| Ligands | 1 | 2005 | 317 | 0.060 |
Why?
|
| Adenoma | 1 | 2004 | 132 | 0.060 |
Why?
|
| Drug Delivery Systems | 1 | 2005 | 236 | 0.050 |
Why?
|
| Enzyme Inhibitors | 1 | 2006 | 659 | 0.050 |
Why?
|
| Octreotide | 1 | 2002 | 21 | 0.050 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2005 | 411 | 0.050 |
Why?
|
| Chemoembolization, Therapeutic | 1 | 2002 | 16 | 0.050 |
Why?
|
| Disease-Free Survival | 2 | 2014 | 349 | 0.050 |
Why?
|
| Mice, Transgenic | 1 | 2005 | 1033 | 0.050 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2002 | 99 | 0.050 |
Why?
|
| Models, Biological | 1 | 2005 | 981 | 0.050 |
Why?
|
| Diagnosis, Differential | 1 | 2004 | 1140 | 0.050 |
Why?
|
| Multivariate Analysis | 2 | 2014 | 1046 | 0.040 |
Why?
|
| Vascular Endothelial Growth Factor B | 2 | 2008 | 8 | 0.040 |
Why?
|
| Seat Belts | 1 | 1997 | 12 | 0.040 |
Why?
|
| Jejunum | 1 | 1997 | 26 | 0.040 |
Why?
|
| Contrast Media | 2 | 2015 | 595 | 0.040 |
Why?
|
| Spinal Fractures | 1 | 1997 | 43 | 0.030 |
Why?
|
| Time Factors | 1 | 2005 | 4655 | 0.030 |
Why?
|
| Survival Analysis | 2 | 2012 | 714 | 0.030 |
Why?
|
| Lumbar Vertebrae | 1 | 1997 | 112 | 0.030 |
Why?
|
| Signal-To-Noise Ratio | 1 | 2015 | 93 | 0.030 |
Why?
|
| Endosonography | 1 | 2016 | 177 | 0.030 |
Why?
|
| Image Enhancement | 1 | 2015 | 143 | 0.030 |
Why?
|
| Capecitabine | 1 | 2014 | 11 | 0.030 |
Why?
|
| Diagnostic Imaging | 1 | 2016 | 201 | 0.030 |
Why?
|
| Tumor Stem Cell Assay | 1 | 2013 | 30 | 0.030 |
Why?
|
| 3' Untranslated Regions | 1 | 2013 | 56 | 0.030 |
Why?
|
| Drug Administration Schedule | 1 | 2014 | 567 | 0.030 |
Why?
|
| Oxidation-Reduction | 1 | 2013 | 567 | 0.020 |
Why?
|
| Adolescent | 1 | 2004 | 8912 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2012 | 536 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2013 | 331 | 0.020 |
Why?
|
| Sex Factors | 1 | 2014 | 1266 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2015 | 2077 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2012 | 1040 | 0.020 |
Why?
|
| Databases, Factual | 1 | 2012 | 622 | 0.020 |
Why?
|
| Age Factors | 1 | 2014 | 1864 | 0.020 |
Why?
|
| Placenta Growth Factor | 1 | 2008 | 12 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor C | 1 | 2008 | 7 | 0.020 |
Why?
|
| Pregnancy Proteins | 1 | 2008 | 15 | 0.020 |
Why?
|
| Half-Life | 1 | 2008 | 96 | 0.020 |
Why?
|
| Culture Media, Conditioned | 1 | 2008 | 78 | 0.020 |
Why?
|
| Logistic Models | 1 | 2012 | 1420 | 0.020 |
Why?
|
| Bevacizumab | 1 | 2007 | 34 | 0.020 |
Why?
|
| Blotting, Northern | 1 | 2007 | 189 | 0.020 |
Why?
|
| Transplantation, Heterologous | 1 | 2007 | 122 | 0.020 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2007 | 160 | 0.020 |
Why?
|
| Chromosome Aberrations | 1 | 2007 | 86 | 0.020 |
Why?
|
| Serotonin | 1 | 2007 | 144 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2012 | 2358 | 0.020 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2007 | 151 | 0.020 |
Why?
|
| Spindle Apparatus | 1 | 2006 | 13 | 0.020 |
Why?
|
| Transcription, Genetic | 1 | 2008 | 562 | 0.020 |
Why?
|
| In Vitro Techniques | 1 | 2007 | 765 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2007 | 507 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2012 | 2007 | 0.020 |
Why?
|
| Duodenoscopy | 1 | 2004 | 15 | 0.020 |
Why?
|
| NF-KappaB Inhibitor alpha | 1 | 2004 | 28 | 0.020 |
Why?
|
| I-kappa B Proteins | 1 | 2004 | 47 | 0.020 |
Why?
|
| Esophagoscopy | 1 | 2004 | 72 | 0.010 |
Why?
|
| Colectomy | 1 | 2004 | 64 | 0.010 |
Why?
|
| Drug Synergism | 1 | 2004 | 260 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 2006 | 742 | 0.010 |
Why?
|
| Adenoviridae | 1 | 2004 | 295 | 0.010 |
Why?
|
| Genetic Vectors | 1 | 2004 | 312 | 0.010 |
Why?
|
| Incidence | 1 | 2007 | 1603 | 0.010 |
Why?
|
| Epithelial Cells | 1 | 2006 | 431 | 0.010 |
Why?
|
| Iodized Oil | 1 | 2002 | 2 | 0.010 |
Why?
|
| Acute Disease | 1 | 2004 | 658 | 0.010 |
Why?
|
| Hydroxyindoleacetic Acid | 1 | 2002 | 36 | 0.010 |
Why?
|
| Gelatin Sponge, Absorbable | 1 | 2002 | 8 | 0.010 |
Why?
|
| Hepatic Artery | 1 | 2002 | 25 | 0.010 |
Why?
|
| Hemostatics | 1 | 2002 | 47 | 0.010 |
Why?
|
| Disease Progression | 1 | 2002 | 1038 | 0.010 |
Why?
|
| Radiotherapy, High-Energy | 1 | 1976 | 8 | 0.010 |
Why?
|
| Lymphedema | 1 | 1976 | 6 | 0.010 |
Why?
|
| Diethylstilbestrol | 1 | 1976 | 45 | 0.010 |
Why?
|
| Mastectomy | 1 | 1976 | 57 | 0.010 |
Why?
|
| Fractures, Bone | 1 | 1997 | 132 | 0.010 |
Why?
|
| Testosterone | 1 | 1976 | 96 | 0.010 |
Why?
|
| Equipment Design | 1 | 1997 | 500 | 0.010 |
Why?
|
| Mammography | 1 | 1976 | 310 | 0.010 |
Why?
|
| Child | 1 | 1997 | 6405 | 0.000 |
Why?
|